|
Video: What is a Stock Split?
|
|
Loxo Oncology is a biopharmaceutical company engaged in the development of selective medicines for patients with genetically defined cancers. Co.'s main product candidate is Larotrectinib, an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. Co.'s drug candidate, LOXO-195 is designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor such larotrectinib, or multikinase inhibitors with anti-TRK activity. Co.'s LOXO-292 targets a cancer oncogene known as Rearranged during Transfection. According to our LOXO stock split history records, LOXO has had 0 splits. | |
|
LOXO (LOXO) has 0 splits in our LOXO stock split history database.
Looking at the LOXO stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into LOXO shares, starting with a $10,000 purchase of LOXO, presented on a split-history-adjusted basis factoring in the complete LOXO stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
08/04/2014 |
|
End date: |
02/15/2019 |
|
Start price/share: |
$13.02 |
|
End price/share: |
$234.66 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
1,702.30% |
|
Average Annual Total Return: |
89.15% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$180,246.40 |
|
Years: |
4.54 |
|
|
|
|
|